HIV, Lipodystrophy
Conditions
Keywords
HIV, Lipodystrophy
Brief summary
In this observational study, the investigators will examine the changes in body composition in HIV-infected subjects before and after initiation of HIV treatment, and look at the correlations with changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.
Detailed description
The effects of lifestyle factors on body composition changes after antiretroviral therapy (ART) are unknown, and as such, investigators will use this prospective observational cohort to study relationships between lifestyle factors, including diet, physical activity and illicit drug use, with changes in body composition after ART. In addition, the effect of the body fat changes will be correlated to changes in cardiometabolic indices such as endothelial function and coronary calcium scoring.
Interventions
DIAGNOSTIC_TESTDual-energy X-ray absorptiometry
Sponsors
University Hospitals Cleveland Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test * Provides written informed consent and is capable of reading and comprehending the informed consent * Is not currently taking antiretroviral therapy and has never been on such treatments in the past. Exception would be for subjects who had been in the past on ≤30 days cumulative antiretrovirals, as long as these were stopped \>6 months prior to study entry * Is planning on starting antiretroviral therapy as part of routine clinic care
Exclusion criteria
* Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body composition measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | Assessed using DEXA (dual energy x-ray absorptiometry) scans which will be quantifying total body fat |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Resting Energy Expenditure (REE) measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | Assessed using a BodyGem REE calculator (values in KCal) |
| endothelial function measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | Assessed using EndoPAT (values reported as a reactive hyperemia index RHI) |
| calcium score measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | Assessed using CT scans |
| central obesity | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | measured with waist circumference using a tape measure (in cm) |
| Lipids measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | used measuring blood levels of triglycerides (mg/dL); serum high-density lipoprotein (mg/dL) ; cholesterol (mg/dL); low density lipoprotein (mg/dL) |
| Fasting plasma glucose measures | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | fasting plasma glucose test is performed after a person has fasted for at least 8 hours (measured in mg/dL) |
| Metabolic syndrome | Baseline, 6-month, 1 year, 2 year, 3 year, 4 year, 5 year | Metabolic syndrome will be defined using the following measures: central obesity, serum triglycerides , serum high-density lipoprotein (HDL); cholesterol levels and fasting plasma glucose |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORGrace McComsey, MD
University Hospitals Cleveland Medical Center
Outcome results
None listed